Short Wave cover image

FDA Approves Aducanumab — A Controversial Drug For Alzheimer's

Short Wave

00:00

Intro

This chapter delves into the controversial approval of the Alzheimer's drug aducanumab, or Aduhelm, examining its claimed benefits against skepticism from experts regarding its effectiveness and safety. It also discusses the financial implications of the drug, highlighting concerns about patient accessibility.

Play episode from 00:00
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app